Evidence map›Paper›PMID 41220757›Full record

ArticleJournal of gastrointestinal oncology2025

Evaluating the cross-reactivity of a stool methylated syndecan-2 (me

Seung Wook Hong, Tae Jeong Oh, Sung Wook Hwang, Sang Hyoung Park, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sungwhan An, Dong-Hoon Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Seung Wook Hong *Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Tae Jeong Oh *Genomictree, Inc., Daejeon, Republic of Korea.
Sung Wook HwangDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Sang Hyoung ParkDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Byong Duk YeDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Jeong-Sik ByeonDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Seung-Jae MyungDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Suk-Kyun YangDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Sungwhan AnGenomictree, Inc., Daejeon, Republic of Korea.
Dong-Hoon YangDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A stool methylated syndecan-2 (me Methods: This study is a prospective, single-centre study. We recruited patients with 13 different types of cancers, including CRC, as positive control. Excluding those with CRC, participants did not undergo colonoscopy. Stool samples were collected from each patient before starting definitive therapy for each cancer and sent to the central lab for methylation analysis. We investigated the cancer incidence rates based on Korean cancer statistics to infer the predicted positivity rates for each cancer type. Results: A total of 168 patients with 13 different types of cancer were included in the study. The positive rate for patients with CRC was 89.5% (17/19). The next highest positive rate was observed in biliary tract cancer at 44.4% (4/9), with the lowest rates being observed in breast cancer at 12.5% (1/8), and in ureter cancer at 12.5% (1/8). The me Conclusions: The stool me

Indexed as

Biomarkercolorectal cancer (CRC)DNA methylationearly detectionsyndecan-2 (SDC2)

Identifiers

PMID41220757
PMCPMC12598348

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.